To be or not to be resilient in familial hypercholesterolaemia: implications for the management

Eur J Prev Cardiol. 2022 May 5;29(5):793-794. doi: 10.1093/eurjpc/zwab197.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anticholesteremic Agents* / therapeutic use
  • Case-Control Studies
  • Cohort Studies
  • Follow-Up Studies
  • Humans
  • Hyperlipoproteinemia Type II* / complications
  • Hyperlipoproteinemia Type II* / diagnosis
  • Hyperlipoproteinemia Type II* / genetics

Substances

  • Anticholesteremic Agents